Clinical Trial

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Name: IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia — clinical trial record (NCT07509086)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.

Trial Details

NCT Number	NCT07509086
Lead Sponsor	The First Hospital of Jilin University
Conditions	Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL)
Enrollment	25 participants
Start Date	2025-12-29
Primary Completion	2028-07-15 (estimated)
Study Completion	2029-07-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-03